Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Allogene Therapeutics (ALLO) Stock Price & Analysis
1,245 Followers
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.01 - $5.78
Previous Close$2.91
Volume1.60M
Average Volume (3M)2.98M
Market Cap
$607.56M
Enterprise Value$311.62M
Total Cash (Recent Filing)$384.86M
Total Debt (Recent Filing)$88.92M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 07, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding170,853,379
10 Day Avg. Volume3,524,945
30 Day Avg. Volume2,984,977
Standard Deviation0.21
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.94
Price to Sales (P/S)4586.06
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.79K
Enterprise Value/Gross Profit3.28K
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$12.70Price Target Upside323.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Allogene Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAllogene plans for a significant fraction of the clinical trial sites to be community-based practices.
Financial StrengthA strong cash position of $497.3MM (pro forma) has been reestablished.
Market ExpansionAllogene announced the company obtained the EU/UK rights for cema-cell, its CD19-directed allogeneic CAR-T products, from Servier.
Bears Say
Cash BurnManagement raised the 2024 cash burn guidance to $200MM, which was previously $190MM.
Development TimelinesThere is uncertainty regarding development timelines, leading to the belief that shares are fairly priced.
Research And DevelopmentR&D expenses were $52.3MM, higher than the estimate of $49.7MM.
---
Ownership Overview
31.74% Insiders
26.59% Mutual Funds
11.66% Other Institutional Investors
30.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $2.01 and its highest was $5.78 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 11 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.03.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.35.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 208,784,410 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went up 2.069%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 24M.
---
Allogene Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.70 (323.33% Upside)
$12.70 (323.33% Upside)
Blogger Sentiment
Neutral
ALLO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 157.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.03%
12-Months-Change
Fundamentals
Return on Equity
-55.06%
Trailing 12-Months
Asset Growth
-21.49%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q1 2024
0:00 / 0:00
---
ALLO Stock 12 Month Forecast
Average Price Target
$12.70
▲(323.33% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Arcturus Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-21.55%
reiterated a buy rating 3 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -21.55% per trade.
---